PUF Ventures Inc. (“PUF” or the “Company“) (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF), an advanced Stage 5 Access to Cannabis for Medical Purposes Regulations (“ACMPR“) license applicant, is pleased to announce that further to its news release of November 29, 2016, the Company has received notice from Health Canada that it has upgraded from position 14 to position 8 with respect to its ACMPR application for majority owned AAA Heidelberg.
“We are very pleased to announce our movement to position 8 with Health Canada as we look to advance to the pre-inspection Stage 6 of the ACMPR application process.” said Derek Ivany, President and CEO of PUF. “We have been working diligently toward our goal of becoming a vertically integrated medical cannabis producer in Canada, and the jump in position with Health Canada brings us another step closer. Stage 5 has been a long but important process and has allowed us to ready the Company for the pre-inspection phase and ultimately licensing. Our recently announced joint venture agreement, with industry leader Canopy Growth Corp., provides PUF with many benefits including a direct sales channel to the marketplace. As was recently outlined in a Health Canada update, several improvements aimed at streamlining and expediting the application process under the ACMPR program have been implemented. Given our strong balance sheet and our near complete facility in London, Ontario, we are hopeful that we will be benefactors of the amended licensing protocols.”
PUF successfully completed and exited Stage 4, the “Security Clearance” stage, and the most difficult milestone, in October 2015. The Company has been steadily progressing through Stage 5, the “Review” stage and has taken the necessary steps to enter Stage 6, the “Pre-Inspection” stage. With several recently announced corporate developments, PUF is updating its business plan to reflect its repositioning as a pure play cannabis producer. It is also taking steps to update its ACMPR application with Health Canada to include Canopy Growth Corp. as the Company’s sole client.
About PUF Ventures Inc.
PUF Ventures Inc. owns a majority interest in AAA Heidelberg, a private Ontario company that is in Stage 5 of 7 in its application for an ACMPR license from Health Canada.  PUF has an option to acquire the balance of shares to own 100% of AAA Heidelberg upon receipt of the ACMPR license.  Through an exclusive joint venture agreement with Canopy Growth Corp., PUF will join CraftGrow, a collection of high-quality cannabis grown by a select and diverse set of producers, made available through the Tweed Main Street website. While it cannot guarantee nor estimate the timing of the issuance of a license to AAA Heidelberg, it is management’s goal to become a leading supplier of medical marijuana in Canada.
VapeTronix, a wholly owned subsidiary of the Company, is in the process of developing Weedbeacon, and expanding its 1313 brand of electronic cigarettes, marijuana vape delivery devices and associated technologies. For more information visit: www.puf.ca.
ON BEHALF OF THE BOARD OF DIRECTORS
Derek Ivany
President & CEO
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.
SOURCE PUF Ventures
For further information: Suite 804 – 750 West Pender Street, Vancouver, BC, V6C 2T7, T: (800) 783-6056, F: (604) 685-6905, W: www.pufventures.com

Source: www.newswire.ca


Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less